We are a fully integrated company capable of developing breakthrough therapies that addresses:

  • High clinical unmet needs,
  • Drug discovery to identify first-in-class medicines by pushing the boundaries of our scientific and medical knowledge
  • Manufacturing processes to generate the highest quality products but with reduced cost of goods to make our medicines widely available

Protein engineering

Applying our industry-leading engineering capabilities to our next generation bispecific antibodies through the use of our autoregulation platform ensures our pipeline products can achieve the maximum efficacy in clinic whilst crucially maintaining the highest levels of patient safety.

Coupling this with our proactive and nimble approach to drug discovery and development maximises the potential of our clinic and pre-clinical portfolio.


With our own process development and analytical development capability within the CMC (Chemistry, Manufacturing and Controls) team, we are able to rapidly develop, industrialise and transfer processes and analytics to our partners for clinical manufacture, test and release ensuring that drug product supply remains off the critical path for our clinical ambitions.

More in this section

Our technologies

We are changing the paradigm of cancer therapy with our immunotherapy technology. 

Read more


NovalGen’s proprietary ground-breaking autoregulation technology platform enables the maximum efficacy to be unleashed from a therapy whilst ensuring a manageable safety profile by limiting life threatening toxicities.

Read more